Key Highlights

  • Avecho Biotechnology (ASX:AVE) traded 13.33% higher at $0.017 during the session on 23 October 2026, while the S&P/ASX 200 was down 0.35%.
  • Its 31 August 2026 announcement said recruitment has recommenced for the final stage of its Phase III insomnia trial.
  • About 320 additional participants are to be enrolled, with recruitment expected to finish within roughly 12 months once more sites are operational.

Avecho Biotechnology Limited (ASX:AVE) shares rose 13.33% to $0.017 during the trading session on Friday 23 October 2026, at 12:04 pm, while the S&P/ASX 200 stood at 8,762.60, down 0.35% (30.60 points). Avecho is a Melbourne-based company developing drug delivery technology and a cannabidiol (CBD) capsule for insomnia. Its latest announcement, dated 31 August 2026, said recruitment had recommenced for the final stage of its Phase III insomnia trial.

Recruitment Restarts for the Second Cohort

In its announcement dated 31 August 2026, Avecho said recruitment has recommenced for the final stage of its pivotal Phase III trial of a TPM-enhanced CBD soft-gel capsule for insomnia. Approximately 320 additional participants are to be enrolled in the second and final cohort, bringing the study to its originally planned size of 519 participants completing the trial.

The company said existing clinical sites have recommenced recruitment and further sites will be activated progressively. Once the additional sites are operational, it expects recruitment of the remaining participants to be completed within approximately 12 months.

Interim Analysis Details Cited in the Update

The 31 August 2026 announcement referred to an interim analysis announced in June 2026. That analysis used data from 244 participants, and the independent Data Monitoring Board recommended unanimously that the trial continue at its originally planned size, without any increase in sample size. The board determined that pre-specified criteria in the trial protocol had been satisfied.

Avecho said the safety data reviewed identified no serious adverse events among the 244 participants across the three treatment groups. The company remains blinded to treatment allocations and efficacy results, which will not be available until the study is completed and the final data are analysed.

Study Design and Dosing

Avecho described the study as a multi-centre, randomised, double-blind and placebo-controlled trial in adults with insomnia. Participants receive a nightly dose of 75mg CBD, 150mg CBD or placebo over an eight-week treatment period, and validated questionnaires and daily sleep diaries are used to assess insomnia severity and sleep quality.

About the Company and Business Overview

Avecho Biotechnology Limited is listed on the ASX under the code AVE and has its office in Clayton, Victoria. The company develops and commercialises human and animal health products using a proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM), which is derived from vitamin E and is described as enhancing the solubility and absorption of drugs and nutrients.

Its lead asset is a proprietary CBD TPM soft-gel capsule, which is in Phase III clinical development for insomnia. Dr Paul Gavin is the Chief Executive Officer. The company said a successful Phase III trial would be its final clinical step supporting a submission to the TGA for registration of the capsule.

Related Sector Context

Biotechnology and drug development companies listed on the ASX are generally pre-revenue and are assessed on clinical milestones, regulatory pathways and funding. Insomnia is described in the announcement as a sleep disorder, with symptoms affecting approximately 10% to 30% of the global population and a cost to the Australian economy estimated at A$19.1 billion.

The announcement also noted regulatory changes in 2020 that allow over-the-counter sales of certain CBD products from pharmacies, subject to approvals. On 23 October 2026, the S&P/ASX 200 was down 0.35% at 8,762.60 at 12:04 pm, while Avecho moved 13.33% higher at a share price of $0.017.

Risks to Weigh In

The trial's efficacy results remain unknown to the company, which is blinded to treatment data. The interim analysis addressed trial size and safety and did not disclose efficacy outcomes, and the final data will be available only after the study is completed. A Phase III trial can also fail to meet its endpoints.

Enrolment of roughly 320 additional participants depends on site activation and patient availability, and the timeline of about 12 months is an expectation. Regulatory approval would require a TGA submission after the trial, and no such approval is stated to be in place. At $0.017, the shares trade at a low absolute price, so small moves produce large percentage changes.

Catalysts on Watch

The company's update points to several milestones. Additional clinical sites are to be activated progressively to accelerate enrolment, and recruitment of the remaining participants is expected to be completed within approximately 12 months once those sites are operational.

After recruitment, participants complete an eight-week treatment period, and the final data will then be analysed. The company stated that a successful trial would support a submission to the TGA for registration of the CBD TPM soft-gel capsule for the management of insomnia.

Where Things Stand

Avecho shares were up 13.33% at $0.017 during the session on 23 October 2026, while the S&P/ASX 200 traded lower. The company's most recent update, dated 31 August 2026, reported that recruitment for the final cohort of its Phase III insomnia trial has recommenced, with efficacy data still to come after the study is completed.